Brian Hansen Sells Shares of SENS $SENS

Key Points

  • Brian Hansen sold 5,420 shares of Senseonics Holdings, Inc. ($SENS) worth $38,915.60.
  • $SENS last traded around $6.69.

Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.

Brian Hansen, Chief Commercial Officer at Senseonics Holdings, Inc. ($SENS), sold 5,420 shares at an average price of $7.18, for a total transaction of $38,915.60. The trade was disclosed in a Form 4 filing with the Securities and Exchange Commission.

Senseonics Holdings, Inc. Stock Down 28.3%

Shares of Senseonics Holdings, Inc. ($SENS) traded around $6.69 on Wednesday, down 28.3% for the day.

Last price$6.69
Market cap$488.03M
Forward P/E-4.74
Beta0.97
52-week low$4.79
52-week high$11.58
50-day MA$6.38
200-day MA$6.58
Current ratio6.75
Quick ratio6.22
Debt-to-equity0.70

Senseonics Holdings, Inc. Earnings

EPS (ttm)-$2.24
Revenue (ttm)$48.55M
Revenue growth117.80%
Net margin-225.34%
Return on equity-118.24%
Next earningsNov 4, 2026

Analysts Set New Price Targets

Average target$13.40
High target$18
Low target$8
Analysts covering5

About Senseonics Holdings, Inc.

Senseonics Holdings, Inc., a commercial-stage medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. Its products include Eversense, Eversense XL, Eversense E3, and Eversense 365, which are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and an app for real-time diabetes monitoring and management. The company serves healthcare providers and patients through a network of distributors and strategic fulfillment partners. Senseonics Holdings, Inc. was founded in 1996 and is headquartered in Germantown, Maryland.

ExchangeNasdaqGS
SectorHealthcare
IndustryMedical Devices
HeadquartersGermantown, MD
CEODr. Timothy T. Goodnow Ph.D.
Employees130

Get Senseonics Holdings, Inc. alerts

New 13F filings, insider trades, and analyst moves on $SENS, sent to your inbox. Free, and you can unsubscribe anytime.

This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.